Veracyte, Inc. (VCYT) News
Filter VCYT News Items
VCYT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VCYT News Highlights
- For VCYT, its 30 day story count is now at 9.
- Over the past 28 days, the trend for VCYT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VCYT are LUNG, ATS and CNS.
Latest VCYT News From Around the Web
Below are the latest news stories about VERACYTE INC that investors may wish to consider to help them evaluate VCYT as an investment opportunity.
Market Mixes It Up With A Broad RallyBiotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. |
Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some InvestorsWith a price-to-sales (or "P/S") ratio of 6x Veracyte, Inc. ( NASDAQ:VCYT ) may be sending very bullish signals at the... |
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate CancerSOUTH SAN FRANCISCO, Calif., May 25, 2023--New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer |
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung CancerSOUTH SAN FRANCISCO, Calif., May 24, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C. |
Veracyte to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., May 23, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences: |
Here's Why This Little-Known Growth Stock Is a BuyBuying growth stocks on the cheap can be a great way to build wealth for investors with enough patience. This is because the strategy combines the high return potential of growth investing with the downside protection that comes with value investing. Diagnostic company Veracyte (NASDAQ: VCYT) looks like it could be a fit for investors seeking a growth stock at a solid value. |
Time To Play Small Cap Life Science StocksThe overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. |
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast CancerSOUTH SAN FRANCISCO, Calif., May 12, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing – specifically, the Prosigna test – |
Something Happened In Biotech Last WeekBiotech stocks were more constructive last week with some sharp moves up. |
Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call TranscriptVeracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript May 4, 2023 Operator: Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2023 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised that today’s conference […] |